SequelSEC

Stemtech Corp STEK

Wholesale-Drugs, Proprietaries & Druggists' Sundries · CIK 0001511820 · Fiscal year ends 1231

Revenue
$2.40M
Fiscal year ended 2026-06-30
Operating income
-$2.42M
Fiscal year ended 2026-06-30
Free cash flow
-$328.76K
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$5.65MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Wholesale-Drugs, Proprietaries & Druggists' Sundries filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.0%0th
Current ratio0.04x0th
Gross margin80.3%100th
Revenue YoY growth-43.1%0th
FCF margin-16.8%14th
Operating margin-94.2%14th

Stemtech Corp (STEK) reported revenue of $2.40M and net income of -$3.84M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Stemtech Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Wholesale-Drugs, Proprietaries & Druggists' Sundries.

Income

Stemtech Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$2.40M
Cost of revenue$546.19K
Gross profit$1.86M
Operating income-$2.42M
Net income-$3.84M
Research & development$0
Weighted-average diluted sharesUnavailable
Pretax income-$3.84M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$4.07M
Selling & marketingUnavailable

Balance

Stemtech Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$3.16M
Current assets$571.23K
Total liabilities$11.11M
Current liabilities$11.11M
Total equity incl. NCI-$8.22M
Temporary (mezzanine) equityUnavailable
Inventory$311.28K
Accounts receivable$0
Goodwill$467.41K
Long-term debt$4.40M
Accounts payableUnavailable

Cash flow

Stemtech Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$328.76K
Capital expenditures$0
Investing cash flow$0
Financing cash flow$85.19K
Net change in cash-$25.68K
Stock-based compensation$439.06K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$167.49K

Derived

Stemtech Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$328.76K
Gross margin77.3%
Operating margin-100.8%
FCF margin-13.7%
SBC / revenue18.3%
Current ratio0.05x
Revenue YoY growth-38.6%
Net margin-159.7%
R&D / revenue0.0%
CapEx / revenue0.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open STEK in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-06-22View SEC filing
10-K · Filed 2026-05-29View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-07-17View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.